Statistically significant area under the curve analysis from Mesoblast's (NASDAQ:MESO) Phase II stem cell product in refractory rheumatoid arthritis (RA) shows that the week 12 positive responses are maintained for 39 weeks. This suggests that the indication could progress into pivotal studies and may attract potential partners. We have increased the RA probability to 35% (formerly 20%). Mesoblast has entered a nine-month exclusive negotiation with Mallinckrodt (NYSE:MNK) (for an A$29.6m investment) on chronic low-back pain and graft vs host disease in transplantation. We have increased our indicative value for Mesoblast to A$1.67bn (A$4.16/share) from A$1.47bn.
Durable responses to iv MPCs in refractory RA
Updated data from the Phase II trial of MPC-300-IV in biologics-refractory RA showed that the improvements in clinical symptoms, function and disease activity seen at week 12 were largely maintained at week 39. In particular, the area under the curve (AUC) analysis of the ARC-N data showed a highly positive statistical significance. The highest dose (2m MPCs/kg) provided the greatest benefit.
To read the entire report Please click on the pdf File Below